Company news
BeyondSpring, Inc. news in 2020
BeyondSpring, Inc.'s news releases, calls and decks from 2020, newest first.
BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors
December 16, 2020
BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium
December 9, 2020
BeyondSpring Announces Pricing of Ordinary Shares
November 18, 2020
BeyondSpring Announces Third Quarter 2020 Financial Results and Provides Business Updates
November 16, 2020
BeyondSpring Announces Proposed Public Offering of Ordinary Shares
November 16, 2020
BeyondSpring Announces Positive Topline Results from its PROTECTIVE-2 Phase 3 Registrational Trial of Plinabulin in Combination with Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia
November 15, 2020
BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Lilly
November 12, 2020
BeyondSpring Appoints Elizabeth Czerepak as Chief Financial Officer
September 21, 2020
BeyondSpring Receives Breakthrough Therapy Designations from Both U.S. FDA and China NMPA for Plinabulin in Chemotherapy-Induced Neutropenia Indication
September 7, 2020
BeyondSpring Provides Second-Quarter 2020 Financial Results and Business Updates
September 2, 2020
BeyondSpring to Host Second-Quarter 2020 Financial Results and Operational Update Conference Call on September 3rd, 2020
August 26, 2020
BeyondSpring Appoints Forty Seven, Inc., Co-Founder and Stanford Hematology Veteran, Dr. Ravindra Majeti, to Board of Directors
August 17, 2020
BeyondSpring Initiates Expanded Access Program with Plinabulin for Patients Suffering from CIN in the U.S.
August 10, 2020
BeyondSpring Announces Positive Topline Interim Results from PROTECTIVE-2 (Study 106) Phase 3 Trial Evaluating Superiority of Plinabulin in Combination with Neulasta for Chemotherapy-Induced Neutropenia Prevention
June 14, 2020
BeyondSpring Reports First-Quarter 2020 Financial Results and Operational Update
June 10, 2020
BeyondSpring Announces Data & Safety Monitoring Board Recommendation for Plinabulin to Continue NSCLC Phase 3 Dublin-3 Study Without Modification
June 2, 2020
BeyondSpring Granted New U.S. Patent for Plinabulin to Treat Severe Chemotherapy-Induced Neutropenia from Taxane in Cancer Patients
May 12, 2020
BeyondSpring Files 2019 Annual Report on Form 20-F
April 29, 2020
BeyondSpring Initiates New Drug Application Rolling Submission for Plinabulin in China for Chemotherapy-Induced Neutropenia
March 29, 2020
BeyondSpring’s Plinabulin May Prevent Tissue Iron Overload in Anemic Cancer Patients Receiving Chronic Blood Transfusions During Chemotherapy
March 22, 2020
BeyondSpring Files for Patent Protection on BPI-002 for the Treatment of Viral Infections Including COVID-19
March 10, 2020
BeyondSpring Appoints Pharma Veterans Drs. Daniel Zabrowski and Ramon Mohanlal to Company’s Board of Directors
January 22, 2020
BeyondSpring Strengthens Executive Rank for Pipeline Expansion and Commercialization Readiness in China
January 5, 2020